Nu-Derm System

Description

It’s what’s inside that counts

Help transform the look of your skin with the#1 physician-dispensed skin care system (1,2)

The Obagi Nu-Derm System plus 1.0% retinol* helps to signifi cantly improve these visible signs of skin aging (1,†,‡:)

• Moderate to severe melasma, unwanted age and sun spots
• Rough, uneven skin• Skin laxity (or looseness)
• The look of fi ne lines and wrinkles

Make Obagi Nu-Derm a part of your daily skin care routine. Contact our offi ce today to see which Obagi Nu-Derm system is right for you!

*Sold separately.
† Study results for a 24-week evaluation of the efficacy and tolerability of twice-daily use of the Obagi Nu-Derm Normal to Oily System with 1.0% retinol; N=33.
‡ If you see no improvement after 12 weeks, please discontinue use of the system. The safety of this system has not been evaluated beyond 24 weeks.
Clear and Blender® in the Obagi Nu-Derm Systems contain 4% hydroquinone.
Important Safety Information for Obagi Nu-Derm Clear and Blender
CONTRAINDICATIONS: People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
WARNINGS:
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.
Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.
Contains sodium metabisulfi te, a sulfi te that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfi te sensitivity in the general population is unknown and probably low. Sulfi te sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.
Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.
Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

Please see full Prescribing Information at: http://www.valeant.com/Portals/25/Pdf/PI/PI_ObagiNu-Derm_Sunfader.pdf

References: 1. OMP, Inc. Data on fi le. 2.Professional Skin Care United States 2014: Key growth drivers and competitive analysis. Parsippany, NJ: Kline & Company, Inc.; 2015.
®/TMs are trademarks of Valeant Pharmaceuticals International, Inc. or its affi liates. All other product or brand names are trademarks of their respective owners. Distributed by Obagi Medical Products, a division of Valeant Pharmaceuticals North America LLC.
©2016 OMP, Inc. NUD.0054.USA.15 01/16